New Two-Target antibody for eczema tested in early trial

NCT ID NCT05859724

Terminated Disease control Sponsor: Yellow Jersey Therapeutics AG Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times

Summary

This early-stage trial tested a new drug called NM26-2198, a bispecific antibody that blocks two inflammatory signals (IL-4R and IL-31) involved in atopic dermatitis (eczema). The study included 126 healthy volunteers and patients with moderate-to-severe eczema, receiving either the drug or a placebo. The main goal was to check safety and how the drug moves through the body. The trial was terminated, so full results may not be available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NM26-2198 (a bispecific antibody targeting IL-4R and IL-31)
What this could lead to: If successful, this could point toward a new treatment option for moderate-to-severe atopic dermatitis that targets two inflammatory pathways at once.
What could go wrong: This was a very early (Phase 1) study focused on safety and dosing, not yet on effectiveness. The trial was terminated, so results may be limited or inconclusive.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS

Contacts and locations

Locations

COPERNICUS Podmiot Leczniczy Sp. z o.o., Szpital Sw. Wojciecha

Gdansk, 80-462, Poland
California Clinical Trials Medical Group (CCTMG) managed by Parexel

Glendale, California, 91206, United States
Centre de Recherche Saint-Louis

Québec, G1W4R4, Canada
D&H Tamarac Research Center

Tamarac, Florida, 33321, United States
DermEffects

London, Ontario, N6H5L5, Canada
First OC Dermatology Research

Fountain Valley, California, 92708, United States
Klinika Ambroziak Dermatologia

Warsaw, 02-953, Poland
Paddington Testing Co.

Philadelphia, Pennsylvania, 19103, United States
Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych

Warsaw, 02-507, Poland
Sadick Research Group

New York, New York, 10075, United States
TCR Medical Corporation

San Diego, California, 92123, United States
UK-SH - Lübeck

Lübeck, Schleswig-Holstein, 23538, Germany
Universitätsklinikum Carl Gustav Carus

Dresden, Saxony, 01307, Germany
Universitätsmedizin Mainz

Mainz, Hesse, 55131, Germany
Uniwersytecki Szpital Kliniczny im. F.Chopina w Rzeszowie

Rzeszów, 35-055, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.